Literature DB >> 10757253

Antidepressant-like activity of amisulpride in two animal models of depression.

M Papp1, J Wieronska.   

Abstract

Clinical reports suggest that amisulpride, in addition to its antipsychotic efficacy, may also have antidepressant properties. The present study was designed to evaluate potential antidepressant-like activity of amisulpride in two behavioural procedures: the forced swim test (FST) and the chronic mild stress (CMS) model. The duration of immobility time in FST was reduced by subchronic (three injections over a 24 h period) administration of imipramine (10 mg/kg) and amisulpride (1 and 3 mg/kg), although the effect of imipramine was more potent. The 5 mg/kg dose of amisulpride was marginally effective and higher doses of 10 and 30 mg/kg were inactive. In CMS, the stress-induced decrease in the consumption of 1% sucrose solution was gradually reversed by chronic treatment with imipramine (10 mg/kg) and amisulpride (5 and 10 mg/kg). Lower (1 or 3 mg/kg) or higher (30 mg/kg) doses of amisulpride were inactive. The magnitude of the effect of active doses of amisulpride in the CMS model was comparable to that of imipramine but its onset of action was faster; at the most active dose of 10 mg/kg, amisulpride significantly increased the sucrose intake in stressed animals within 2 weeks of treatment while imipramine required 4 weeks before first effects on the stress-induced deficit in sucrose consumption could be observed. These results provide further support for clinical observations that amisulpride may possess potent and rapid antidepressant activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757253     DOI: 10.1177/026988110001400106

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  Gamma-Hydroxybutyrate Increases Resting-State Limbic Perfusion and Body and Emotion Awareness in Humans.

Authors:  Oliver G Bosch; Fabrizio Esposito; Michael M Havranek; Dario Dornbierer; Robin von Rotz; Philipp Staempfli; Boris B Quednow; Erich Seifritz
Journal:  Neuropsychopharmacology       Date:  2017-05-31       Impact factor: 7.853

2.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

3.  An animal model of a behavioral intervention for depression.

Authors:  Daniela D Pollak; Francisco J Monje; Lee Zuckerman; Christine A Denny; Michael R Drew; Eric R Kandel
Journal:  Neuron       Date:  2008-10-09       Impact factor: 17.173

4.  CB1 cannabinoid receptors are involved in neuroleptic-induced enhancement of brain neurotensin.

Authors:  Parichehr Hassanzadeh; Fatemeh Rostami
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

Review 5.  The chronic mild stress (CMS) model of depression: History, evaluation and usage.

Authors:  Paul Willner
Journal:  Neurobiol Stress       Date:  2016-08-24

6.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.